Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML
Sponsor: AVEO Pharmaceuticals, Inc.
Terminated
Low Accrual
Other terminated trials from AVEO Pharmaceuticals, Inc.
- Hepatocellular Carcinoma · Phase PHASE1/PHASE2 · Apr 2023
- Non-small Cell Lung Cancer · Phase PHASE2 · Jan 2017
- Carcinoma, Squamous Cell of Head and Neck · Phase PHASE1 · Sep 2016
- Fallopian Tube Cancer · Phase PHASE2 · Jan 2016
- Solid Tumors · Phase NA · Oct 2015
More terminations from AVEO Pharmaceuticals, Inc.
Other Acute Myeloid Leukemia trials with similar outcome
This PHASE1 trial investigates Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia and is currently terminated or withdrawn. AVEO Pharmaceuticals, Inc. leads this study, which shows 10 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Apr 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Apr 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AVEO Pharmaceuticals, Inc.
- C. Babis Andreadis
- Gateway for Cancer Research
For direct contact, visit the study record on ClinicalTrials.gov .